Zobrazeno 1 - 6
of 6
pro vyhledávání: '"M S Schou"'
Autor:
S Parveen, M M Malmborg, A A Arulmurugananthavadivel, L K Koeber, N C Carlson, C A Andersson, D Z Zahir, M M Malik, E F Fosboel, G G Gislason, M S Schou
Publikováno v:
European Heart Journal. 43
Background Nonsteroidal, selective mineralocorticoid receptor antagonists (MRAs) have been shown to reduce cardiovascular events among patients with diabetic nephropathy, a clinical syndrome characterized by persistent albuminuria. However, prior rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e1d1758713fdb7b9a613002b738e744
https://doi.org/10.1093/eurheartj/ehac544.2409
https://doi.org/10.1093/eurheartj/ehac544.2409
Autor:
D Zahir, C M Madelaire, E F Fosboel, L K Kober, G G Gislason, C G Garred, A N B Bonde, C A Andersson, M S Schou
Publikováno v:
European Heart Journal. 43
Background Renal endpoints like end stage renal disease (ESRD) and a 50% decline in estimated glomerular filtration rate (eGFR) have been used in recent randomized clinical trials in heart failure (HF). However, the distribution of these events in la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0297d02583f39c3a1e6dcf4ea961b23f
https://doi.org/10.1093/eurheartj/ehac544.877
https://doi.org/10.1093/eurheartj/ehac544.877
Autor:
Torp-Pedersen Ct, M S Schou, G G Gislason, Bochra Zareini, Lars Koeber, Paul Blanche, C S Selmer, Anders Holt, S L K Kristensen, M L Lamberts, Deepthi Rajan, M.M Malik
Publikováno v:
European Heart Journal. 41
Background Development of type 2 diabetes (T2D) is common in patients with heart failure (HF), but knowledge of future cardiovascular events is lacking. Purpose We compared risk of heart failure hospitalization (HFH) or death versus ischemic events i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3052eae1f45a21f0c95d2273341a50c
https://doi.org/10.1093/ehjci/ehaa946.1145
https://doi.org/10.1093/ehjci/ehaa946.1145
Autor:
Lars Koeber, Paul Blanche, M S Schou, M L Lamberts, S L K Lund Kristsensen, Christian Torp-Pedersen, G G Gislason, M D D D'Souza Diederichsen, Bochra Zareini, M E M Elmegaard Malik, C S Selmer
Publikováno v:
European Heart Journal. 40
Background Recent studies have highlighted a high incidence of heart failure (HF) in type 2 diabetes mellitus (T2D), but it remains unclear how the development of HF affects prognosis compared to other T2D complications. Purpose To estimate the risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edf7524fed241936a8ec365604183903
https://doi.org/10.1093/eurheartj/ehz745.0053
https://doi.org/10.1093/eurheartj/ehz745.0053
Autor:
M L Lamberts, C T Pedersen, M E Malik, Lars Koeber, Paul Blanche, M S Schou, Bochra Zareini, C M R Rasmussen, J M McMurray, S L K Kristensen, N S Sattar, G G Gislason, Maria D'Souza, C A Andersson
Publikováno v:
European Heart Journal. 40
Background Reflecting recent clinical trial findings, updated type 2 diabetes (T2D) guidelines recommend targeting SGLT2 inhibitors at patients at risk of heart failure (HF)-related events and GLP-1 receptor agonists at those at greater risk of ather
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03165a7731b4bff6576e8e3e6944c9bb
https://doi.org/10.1093/eurheartj/ehz747.0104
https://doi.org/10.1093/eurheartj/ehz747.0104
Autor:
M S Schou, M L Lamberts, G G Gislason, Anders Holt, Christian Selmer, M J Jensen, R Roerth, S L K Kristensen, Bochra Zareini
Publikováno v:
European Heart Journal. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ace1c0d8148a58d2b153808db72f4ba4
https://doi.org/10.1093/eurheartj/ehy565.p1820
https://doi.org/10.1093/eurheartj/ehy565.p1820